Prominent Diabetic Peripheral Neuropathy Market Trend for 2025: Advancements In Non-Opioid Pain Treatments For Neuropathy

What industry-specific factors are fueling the growth of the diabetic peripheral neuropathy market?
The increase in obesity-related health issues is expected to drive the growth of the diabetic peripheral neuropathy (DPN) market. Obesity, characterized by excessive body fat accumulation, significantly increases the risk of chronic diseases, including type 2 diabetes. This, in turn, heightens the occurrence of diabetic peripheral neuropathy, a complication where high blood sugar levels cause nerve damage. The rising global prevalence of obesity is linked to increased awareness, lifestyle changes, and growing demand for preventive and treatment solutions, all of which are contributing to the demand for better DPN management. In March 2024, the World Health Organization (WHO) reported that 43% of adults were overweight, with 16% classified as obese, while childhood obesity is also on the rise. As obesity-related health issues increase, so does the need for treatments addressing complications like diabetic peripheral neuropathy, further fueling the market growth.

Get Your Diabetic Peripheral Neuropathy Market Report Here:
https://www.thebusinessresearchcompany.com/report/diabetic-peripheral-neuropathy-global-market-report

What Is the projected market size and growth rate for the diabetic peripheral neuropathy market?
The diabetic peripheral neuropathy market has experienced strong growth, expanding from $3.51 billion in 2024 to $3.84 billion in 2025 at a CAGR of 9.4%. The market's historical growth has been driven by a rising geriatric population, increasing diabetes prevalence, higher healthcare expenditures, greater awareness of diabetic complications, and improved healthcare infrastructure.

The diabetic peripheral neuropathy market is forecasted to grow significantly, reaching $5.43 billion by 2029 at a CAGR of 9.1%. Growth drivers include an increase in sedentary lifestyles, greater government initiatives and funding, rising prevalence of neuropathy risk factors, improved diagnostic precision, and heightened support for early detection and prevention. Notable trends include advances in diagnostic technologies, technological improvements in treatment options, increased R&D investments, the development of minimally invasive procedures, and a stronger emphasis on collaborative research and development.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21170&type=smp

What new trends are reshaping the diabetic peripheral neuropathy market and its opportunities?
In the diabetic peripheral neuropathy (DPN) market, companies are exploring NaV1.8 pain signal inhibitors for non-opioid pain management. For instance, in April 2024, Vertex Pharmaceuticals Incorporated, a US-based biotech company, advanced its suzetrigine pain program, including a Phase 3 pivotal program for treating DPN pain. Suzetrigine selectively inhibits NaV1.8, a key pain mediator in sensory neurons, showing promising results in earlier studies and receiving FDA breakthrough therapy designation for DPN pain management.

What major market segments define the scope and growth of the diabetic peripheral neuropathy market?
The diabetic peripheral neuropathy market covered in this report is segmented -

1) By Disease: Type 2 Diabetic Peripheral Neuropathy, Type 1 Diabetic Peripheral Neuropathy
2) By Treatment: Pain Management Drugs, Gene Therapies
3) By Therapy: Antidepressants, Anticonvulsants
4) By Patient Population: Adult Patients, Geriatric Patients

Subsegments:
1) By Type 2 Diabetic Peripheral Neuropathy: Sensory Neuropathy, Motor Neuropathy, Autonomic Neuropathy
2) By Type 1 Diabetic Peripheral Neuropathy: Distal Symmetric Neuropathy, Mononeuropathy, Polyradiculopathy

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21170

Which region dominates the diabetic peripheral neuropathy market?
North America was the largest region in the diabetic peripheral neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic peripheral neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which key market leaders are driving the diabetic peripheral neuropathy industry growth?
Major companies operating in the diabetic peripheral neuropathy market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc., Eli Lilly and Company, Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Sun Pharmaceutical Industries Limited, Lupin Pharmaceuticals Inc., Chemie Grünenthal GmbH, Alkem Laboratories Limited, Acorda Therapeutics Inc., Mitsubishi Tanabe Pharma Corporation, NeuroMetrix Inc., Regenacy Pharmaceuticals Inc., Helixmith Co. Ltd., Aptinyx Inc., WinSanTor Inc., Sonnet BioTherapeutics Holdings Inc., OLYS Pharma Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21170&type=smp

What Is Covered In The Diabetic Peripheral Neuropathy Global Market Report?

•Market Size Forecast: Examine the diabetic peripheral neuropathy market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the diabetic peripheral neuropathy market for a structured understanding.
•Key Players Overview: Analyze major players in the diabetic peripheral neuropathy market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the diabetic peripheral neuropathy market.
•Segment Contributions: Evaluate how different segments drive overall growth in the diabetic peripheral neuropathy market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the diabetic peripheral neuropathy market.
•Industry Challenges: Identify potential risks and obstacles affecting the diabetic peripheral neuropathy market.
•Competitive Landscape: Review strategic developments in the diabetic peripheral neuropathy market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.